My watch list
my.bionity.com  
Login  

GVK Biosciences announces multi-year drug discovery collaboration with the Moulder Center for Drug Discovery Research, Temple University

30-Nov-2011

GVK Biosciences announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.  As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders.

The Moulder Center is a unique, fully integrated state-of-the-art drug discovery center that is used for both internal research within Temple University and for external collaborations with pharmaceutical and biotech companies and other universities. As part of the collaboration, GVK BIO will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against selected targets. GVK Biosciences will be responsible for reagent generation, assay development and establishing the screening cascade leading to lead identification and optimization. Moulder Center and GVK BIO will be jointly responsible for designing the molecules for this program. The molecules will be optimized and progressed through lead optimization to a pre-clinical candidate.

“Utilizing GVK BIO’s discovery chemistry and biology capabilities, we look forward to working with the Moulder Center for Drug Discovery Research.  Dr. Magid Abou-Gharbia, is a world renowned researcher with more than 26 years of research experience and we are pleased to be working with him.  This collaboration with Temple University is among several academic collaborations GVK BIO has with leading research institutions.  ” said Manni Kantipudi, Chief Executive Officer, GVK Biosciences.

“This business model reflects the increasing trend of collaborations between academic centers of excellence and pharmaceutical companies to discover new drugs.” said Dr. Magid Abou-Gharbia, Director of the Moulder Center for Drug Discovery Research and Associate Dean for Research in Temple’s School of Pharmacy  “We are delighted to be working with GVK BIO’s experienced research and discovery team to further leverage both teams’ talents to identify innovative drug candidates”.

Facts, background information, dossiers
More about GVK Biosciences
More about Temple University
  • News

    Key factor in mitochondrial calcium uptake and bioenergetics identified

    Mitochondria are the energy-generating batteries of cells, but they also perform other critical functions, including protecting cells against calcium overload, a significant cause of cell death in certain cardiovascular and neurodegenerative diseases. Underlying this safety mechanism is a p ... more

    Small molecule inhibitor shows promise in precision cancer targeting

    Cancer cells with mutations in BRCA1 or BRCA2 genes, which serve a vital role in preserving the integrity of the genetic code, are key targets for cancer therapeutics. Yet, few agents can selectively eliminate cells deficient in BRCA, and none can do so without the risk of inducing drug res ... more

    Blinded by genetic mutation

    Achromatopsia is a rare, inherited vision disorder that affects the eye's cone cells, resulting in problems with daytime vision, clarity and color perception. It often strikes people early in life, and currently there is no cure for the condition. One of the most promising avenues for devel ... more

  • Universities

    Temple University

    Founded in 1884 by Dr. Russell Conwell, Temple College became Temple University in 1907 and has evolved into a comprehensive urban research and academic institution. more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE